로딩 중…
지수 로딩 중…
HLB PANAGENE Co., LTD.
046210· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,336+6.12%
2026-11-02
Financials
Valuation Metrics
HLB PANAGENE Co., LTD.'s Market Cap is ₩612B. At end of 2025 it was ₩790B. Ranked #1579 of 2,405 in KR market (top 66%), #926 of 1,627 on KOSDAQ (top 57%), #174 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 61.19B KRW | KR#1,579/2,405 Sec#174/231 |
| Revenue | 14.71B KRW | KR#2,208/2,405 Sec#166/231 |
| Net Income | -3.28B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 81.74B KRW | KR#1,920/2,405 Sec#158/231 |
| Net Assets | 73.64B KRW | KR#1,640/2,405 Sec#134/231 |
| Employees | 81 | KR#1,798/2,405 Sec#150/231 |
| Value | ||
| P/B | 0.83x | KR#1,361/2,405 Sec#84/231 |
| P/S | 4.14x | KR#2,111/2,405 Sec#142/231 |
| FCF Yield | -4.08% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -4.45% | KR#1,776/2,405 Sec#127/231 |
| ROA | -4.01% | KR#1,881/2,405 Sec#135/231 |
| Op. Margin | -23.21% | KR#2,132/2,405 Sec#149/231 |
| Revenue Growth | 1.40% | KR#1,427/2,405 Sec#142/231 |
| Earnings Growth | -166.48% | KR#1,215/2,405 Sec#80/231 |
| Financial Health | ||
| Debt Ratio | 10.99% | KR#160/2,405 Sec#33/231 |
| Total Debt | 6.07B KRW | KR#1,739/2,405 Sec#166/231 |
| FCF | -2.50B KRW | KR#1,364/2,405 Sec#106/231 |
| Cash | 20.46B KRW | KR#1,239/2,405 Sec#90/231 |
| Current Ratio | 4.94x | KR#288/2,405 Sec#50/231 |
| Performance | ||
| 1Y Return | -20.81% | KR#1,089/2,405 Sec#69/231 |
| 1M Return | 8.62% | KR#118/2,405 Sec#9/231 |
| From 52W High | -54.56% | KR#1,377/2,405 Sec#110/231 |
| 1Y MDD | -62.30% | KR#1,570/2,405 Sec#127/231 |
| Trading | ||
| Volume | 185,730 shares | KR#404/2,405 Sec#39/231 |
| Trading Value | 244.6M KRW | KR#1,052/2,405 Sec#117/231 |
| Foreign Own. | 1.51% | KR#1,822/2,405 Sec#180/231 |
| Per Share | ||
| EPS | -72 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,618 KRW | KR#2,163/2,405 Sec#184/231 |
Company Info
동사는 2001년 설립, 2008년 코스닥 상장, 2023년 상호를 에이치엘비파나진으로 변경함. 주력 사업은 인공 유전자인 PNA를 활용한 소재 및 분자진단 사업을 포함하며, (주)바이오스퀘어는 퀀텀팩 기술로 플랫폼 사업 확장 중임. AI 기반 진단 플랫폼 구축, PNA 신약개발로 예방, 진단, 치료를 아우르고 의료 밸류체인 확보하여 정밀진단 종합 솔루션 확대 추진하고 있음. HLB파나진는 1976년에 설립되었으며 대전광역시 유성구에 본사를 두고 있습니다.